Structure via PubChem · Public domain (PubChem)
perifosine
Sign in to saveAlso known as D 21266, KRX-0401, NSC 639966
Perifosine (also KRX-0401) is a former drug candidate that was under development for a variety of cancer indications. It is an alkyl-phospholipid structurally related to miltefosine. Perifosine interrupts the PI3K/AKT/mTOR pathway by acting as an allosteric AKT inhibitor targeting the pleckstrin homology domain of AKT. It was being developed by Keryx Biopharmaceuticals who had licensed it from Æterna Zentaris Inc.
Chemical data
- Formula
- C25H52NO4P
- Molecular weight
- 461.7 g/mol
- IUPAC name
- (1,1-dimethylpiperidin-1-ium-4-yl) octadecyl phosphate
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- chronic lymphocytic leukemia, lymphoma, leukemia, neoplasm
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 461.363396
Show 3 more facts
- chemical formula
- C₂₅H₅₂NO₄P
- canonical SMILES
- CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](CC1)(C)C
- Commons category
- Perifosine
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Perifosine (also KRX-0401) is a former drug candidate that was under development for a variety of cancer indications. It is an alkyl-phospholipid structurally related to miltefosine. Perifosine interrupts the PI3K/AKT/mTOR pathway by acting as an allosteric AKT inhibitor targeting the pleckstrin homology domain of AKT. It was being developed by Keryx Biopharmaceuticals who had licensed it from Æterna Zentaris Inc.
In 2010, perifosine received orphan drug status in the U.S. for the treatment of multiple myeloma and neuroblastoma, and for multiple myeloma in the EU. However, both were later withdrawn.
Excerpted from Wikipedia’s “perifosine” article, available under the CC BY-SA 4.0 licence.